Search results for "Reno"

showing 10 items of 1031 documents

Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2).

2003

X-linked adrenoleukodystrophy (X-ALD) is a demyelinating disorder associated with impaired very-long-chain fatty-acid (VLCFA) beta-oxidation caused by mutations in the ABCD1 (ALD) gene that encodes a peroxisomal membrane ABC transporter. ABCD2 (ALDR) displays partial functional redundancy because when overexpressed, it is able to correct the X-ALD biochemical phenotype. The ABCD2 promoter contains a putative thyroid hormone-response element conserved in rodents and humans. In this report, we demonstrate that the element is capable of binding retinoid X receptor and 3,5,3'-tri-iodothyronine (T3) receptor (TRbeta) as a heterodimer and mediating T3 responsiveness of ABCD2 in its promoter conte…

MaleThyroid HormonesReceptors Retinoic AcidGene ExpressionATP-binding cassette transporterRetinoid X receptorRats Sprague-DawleyMiceABCD3Gene expressionABCD2medicineAnimalsHumansReceptorAdrenoleukodystrophyPromoter Regions GeneticGeneCells CulturedRepetitive Sequences Nucleic AcidPharmacologyChemokine CCL22Mice KnockoutReceptors Thyroid Hormonebiologymedicine.diseaseCell biologyRatsUp-RegulationOligodendrogliaRetinoid X ReceptorsLiverAstrocytesChemokines CCbiology.proteinCancer researchMolecular MedicineTriiodothyronineAdrenoleukodystrophyChemokine CCL17Transcription FactorsMolecular pharmacology
researchProduct

Effects of beta-adrenoceptor drug stimulation on various models of gastric ulcer in rats.

1982

Abstract 1. Experiments were designed to evaluate the effect of the pharmacological activation of beta-adrenoceptors on various models of gastric ulcer in the rat. 2. Pretreatment with the beta-adrenoceptor stimulant drugs, isoprenaline or salbutamol, significantly inhibited stress-induced gastric ulcers. This anti-ulcer effect was abolished by propranolol but not by atenolol, suggesting that beta 2-adrenoceptors mediate this response. 3. In the pylorus-ligation model, salbutamol inhibited lesion formation and reduced the intragastric content of hydrogen ions, histamine and pepsin although the latter was only affected with the higher dose of salbutamol. 4. Salbutamol also prevented the ulce…

MaleTime FactorsStimulationPropranololPharmacologychemistry.chemical_compoundIsoprenalinemedicineGastric mucosaAnimalsHumansAlbuterolStomach UlcerPylorusPharmacologybusiness.industryIsoproterenolRats Inbred StrainsReserpineAdrenergic beta-AgonistsAtenololdigestive system diseasesRatsmedicine.anatomical_structurechemistryGastric MucosaAnesthesiaSalbutamolbusinessHistamineStress Psychologicalmedicine.drugResearch ArticleBritish journal of pharmacology
researchProduct

Incidence of Abcd1 level on the induction of cell death and organelle dysfunctions triggered by very long chain fatty acids and TNF-alpha on oligoden…

2012

X-linked adrenoleukodystrophy (X-ALD) is characterized by ABCD1 deficiency. This disease is associated with elevated concentrations of very long chain fatty acids (C24:0 and C26:0) in the plasma and tissues of patients. Under its severe form, brain demyelination and inflammation are observed. Therefore, we determined the effects of C24:0 and C26:0 on glial cells:oligodendrocytes, which synthesize myelin, and astrocytes, which participate in immune response. So, 158N murine oligodendrocytes, rat C6 glioma cells, rat primary cultures of neuronal-glial cells, and of oligodendrocytes were treated for various periods of time in the absence or presence of C24:0 and C26:0 used at plasmatic concent…

MaleTime FactorsVacuoleMitochondrionToxicologyATP Binding Cassette Transporter Subfamily D Member 1chemistry.chemical_compoundMice0302 clinical medicineRNA Small InterferingAdrenoleukodystrophyCells CulturedComputingMilieux_MISCELLANEOUSMembrane Potential MitochondrialNeurons0303 health sciencesGeneral NeuroscienceFatty AcidsBrainPeroxisomeCatalaseFlow Cytometry3. Good healthCell biologyMitochondriaOligodendrogliamedicine.anatomical_structureFemaleProgrammed cell deathChromatography GasBiologyGas Chromatography-Mass SpectrometryStatistics Nonparametric03 medical and health sciencesMicroscopy Electron TransmissionLysosomeOrganellemedicineAnimalsHumansPropidium iodideRNA MessengerRats Wistar030304 developmental biologyCell SizeChemokine CCL22OrganellesDose-Response Relationship DrugCell growthTumor Necrosis Factor-alphaRatschemistryAnimals NewbornAstrocytesATP-Binding Cassette Transporters[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgery
researchProduct

Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2)

2001

X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disease due to a defect in the ABCD1 (ALD) gene. ABCD1, and the two close homologues ABCD2 (ALDR) and ABCD3 (PMP70), are genes encoding ATP-binding cassette half-transporters of the peroxisomal membrane. As overexpression of the ABCD2 or ABCD3 gene can reverse the biochemical phenotype of X-ALD (reduced beta-oxidation of very-long-chain fatty acids), pharmacological induction of these partially redundant genes may represent a therapeutic approach to X-ALD. We previously reported that the ABCD2 and ABCD3 genes could be strongly induced by fibrates, which are hypolipidaemic drugs and peroxisome-proliferators in rodents. We provide e…

MaleTranscription GeneticMolecular Sequence DataResponse elementReceptors Cytoplasmic and NuclearATP-binding cassette transporterATP Binding Cassette Transporter Subfamily DBiochemistryMiceFenofibrateABCD3Sequence Homology Nucleic AcidABCD2medicineAnimalsHumansRats WistarAdrenoleukodystrophyPromoter Regions GeneticGeneHypolipidemic AgentsMice KnockoutBase SequencebiologyDNATransfectionPeroxisomemedicine.diseaseMolecular biologyRatsGene Expression Regulationbiology.proteinATP-Binding Cassette TransportersAdrenoleukodystrophyTranscription FactorsEuropean Journal of Biochemistry
researchProduct

Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

2016

Background and objective: Statin-induced myopathy (SIM) has been partially attributed to deficiency of dolichol and coenzyme Q10 (CoQ10). We aimed to test the safety and efficacy of plant polyprenols in combination with CoQ10 for alleviation of SIM. Materials and methods: In an open-label, one-center prospective pilot study patients with SIM received conifer-tree needle polyprenols (4 mg/day) and CoQ10 (100 mg/day) for 8 weeks. Symptoms and safety were evaluated according to symptom severity score (0–10), creatine kinase (CK) levels, exercise test, dynamometry, complete blood count, clinical biochemistry and electrocardiography. Results: Of the 14 patients, 11 completed the study per protoc…

MaleUbiquinoneMyopathyPilot Projects030204 cardiovascular system & hematologyGastroenterologyElectrocardiography0302 clinical medicine030212 general & internal medicineProspective StudiesProspective cohort studyPain MeasurementAged 80 and overMedicine(all)lcsh:R5-920Muscle Weaknessbiologymedicine.diagnostic_testComplete blood countMiddle AgedTreatment OutcomeDrug Therapy CombinationFemalemedicine.symptomlcsh:Medicine (General)Glomerular Filtration Ratemedicine.medical_specialtyStatinmedicine.drug_classRenal functionAsymptomaticPolyprenols03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMyopathyAgedbusiness.industryTerpenesStatinsMyalgiamedicine.diseaseTracheophytaAutomotive EngineeringPhysical therapybiology.proteinExercise TestCoenzyme Q10Creatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessStatins; Myopathy; Polyprenols; Coenzyme Q10; UbiquinoneBiomarkersKidney diseaseMedicina
researchProduct

Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury …

2019

Background.Xenon is a noble gas with neuroprotective properties. We previously showed that xenon improves short and long-term outcomes in young adult mice after controlled cortical impact (CCI). This is a follow-up study investigating xenon’s effect on very long-term outcome and survival. Methods.C57BL/6N (n=72) young adult male mice received single CCI or sham surgery and were treated with either xenon (75%Xe:25%O2) or control gas (75% N2:25%O2). The outcomes used were: 1) 24-hour lesion volume and neurological outcome score; 2)contextual fear-conditioning at 2 weeks and 20 months; 3) corpus callosum white matter quantification; 4) immunohistological assessment of neuroinflammation and neu…

MaleXenonhippocampusnerve degenerationCorpus callosumBUPRENORPHINEneuroinflammationMice0302 clinical medicineCognition030202 anesthesiologyAnesthesiologyBrain Injuries TraumaticMedicineEPIDEMIOLOGYYoung adultmemory disordersNeuronstraumatic brain injurySham surgeryBrain3. Good healthD-ASPARTATE RECEPTORmedicine.anatomical_structureNeuroprotective AgentsAnesthesianeuroprotectionmedicine.symptomLife Sciences & BiomedicineTraumatic brain injuryHYPOPITUITARISMNeuroprotectionWhite matter03 medical and health sciencesANALGESIAINHALED XENONAnimalsgeneral anaesthesiaSurvival analysisHYPOTHERMIAInflammationScience & Technologybusiness.industry1103 Clinical SciencesHypothermiamedicine.diseaseCOMPETITIVE-INHIBITIONSurvival AnalysisMice Inbred C57BLPATHOLOGYDisease Models AnimalAnesthesiology and Pain MedicineChronic DiseasebusinessCognition Disorders030217 neurology & neurosurgeryWHITE-MATTER DAMAGEFollow-Up StudiesBritish journal of anaesthesia
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct

Selective bilateral blood sampling from the inferior petrosal sinus in Cushing's disease: effects of corticotropin-releasing factor and thyrotropin-r…

1993

We sought to enhance the sensitivity of selective bilateral blood sampling to determine adrenocorticotropin (ACTH) and prolactin levels in the inferior petrosal sinus (IPS) by administering two stimulatory agents--corticotropin-releasing factor (CRF) and thyrotropin-releasing hormone (TRH). We then determined the ACTH and prolactin levels in the IPS of 10 patients with Cushing's disease. After peripheral administration of both CRF and TRH, ACTH levels were significantly higher on the tumor side in all patients. The prolactin level was significantly higher on the tumor side when CRF or TRH was used to stimulate pituitary secretion. Postsurgical immunohistochemistry studies revealed productio…

Maleendocrine systemPituitary glandmedicine.medical_specialtyCorticotropin-Releasing HormoneThyrotropin-releasing hormonePituitary neoplasmPetrosal Sinus SamplingSensitivity and SpecificityCushing syndromeAdrenocorticotropic HormonePituitary Gland AnteriorInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingPituitary NeoplasmsCushing SyndromeThyrotropin-Releasing Hormonebusiness.industryInferior petrosal sinusCushing's diseasemedicine.diseaseProlactinProlactinmedicine.anatomical_structureEndocrinologyFemaleCardiology and Cardiovascular Medicinebusinesshormones hormone substitutes and hormone antagonistsBlood samplingCardiovascular and interventional radiology
researchProduct

Cortisol reactivity in social anxiety disorder: A highly standardized and controlled study.

2020

Abstract In order to understand the psychopathology of the social anxiety disorder (SAD) at the neuroendocrine level, standardized experimental studies on endocrine and physiological markers are necessary, especially since empirical data are still ambiguous. Hence, differences in both, the autonomic nervous system (ANS) and the endocrine stress responses (ACTH, salivary and plasma cortisol) were investigated in a particularly homogenous sample after a standardized stressor (Trier Social Stress Test). The sample consisted of n  = 35 patients with SAD, age, and gender matched to n  = 35 healthy controls (HC). In terms of the heart rate, the response pattern was comparable in both groups. Conc…

Maleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismStimulus (physiology)03 medical and health sciences0302 clinical medicineEndocrinologyAdrenocorticotropic HormoneInternal medicineHeart ratemedicineTrier social stress testEndocrine systemHumansSalivaBiological PsychiatryEndocrine and Autonomic Systemsbusiness.industryStressorSocial anxietyPhobia Social030227 psychiatryPsychiatry and Mental healthAutonomic nervous systemEndocrinologyCase-Control StudiesFemalebusiness030217 neurology & neurosurgeryPsychopathologyPsychoneuroendocrinology
researchProduct